CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue
Housing	$ 0	$ 0	$ 80,650	$ 0
Commercial rental - related party	0	0	0	0
Tissue array products	85,519	138,727	153,655	289,879
Total revenue	85,519	138,727	234,305	289,879
Cost of Sales
Housing	0	0	47,145	0
Commercial rental - related party	7,365	4,566	33,664	21,262
Tissue array products	72,157	84,815	140,227	183,335
Total cost of sales	79,522	89,381	221,036	204,597
Gross Profit	5,997	49,346	13,269	85,282
Operating Expenses:
Salaries and wages	54,772	42,050	105,760	95,963
Depreciation and amortization	2,430	5,991	13,852	39,436
Bad debt expense	0	0	0	6,630
Professional fees	19,174	14,457	57,749	54,564
Selling and distribution expenses	1,733	1,918	4,594	6,104
Other general and administrative expenses	49,699	107,485	173,237	135,077
Total Operating Expenses	127,808	171,901	355,192	337,774
Loss from Operations	(121,811)	(122,555)	(341,923)	(252,492)
Other Income (Expense)
Interest expenses	(38,014)	(61,610)	(85,486)	(107,798)
Other income (expense), net	(22,028)	26,614	(22,795)	24,566
Total Other Expense, Net	(60,042)	(34,996)	(108,281)	(83,232)
Loss before Income Taxes	(181,853)	(157,551)	(450,204)	(335,724)
Income Tax Expense	0	142	(1,738)	284
Net loss	(181,853)	(157,693)	(448,466)	(336,008)
Less: Net loss attributable to the non-controlling interests	(55,886)	(32,442)	(89,366)	(63,935)
Net loss attributable to CYBRDI, INC.	(125,967)	(125,251)	(359,100)	(272,073)
Foreign currency translation loss	(45,257)	33,685	(115,813)	(3,409)
Comprehensive loss	$ (171,224)	$ (91,566)	$ (474,913)	$ (275,482)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted Average Number of Shares Outstanding
Basic and Diluted	120,225,323	120,225,323	120,225,323	120,225,323